Firm also plans for new ownership, recapitalizationImaging services provider Alliance Imaging is diversifying its portfolio. The Anaheim, CA-based company has purchased Acclaim Medical, a Southern California-based mobile PET services provider.
Firm also plans for new ownership, recapitalization
Imaging services provider Alliance Imaging is diversifying its portfolio. The Anaheim, CA-based company has purchased Acclaim Medical, a Southern California-based mobile PET services provider. Terms were not released.
As rationale for the deal, Alliance executives pointed to recent approvals of reimbursement for PET scans for selected cancer detection procedures by the Health Care Financing Administration. The firm now believes PET is a commercially viable technology.
PET is a cutting-edge modality, and were looking to expand our business, said Michael Grismer, vice president and controller. Its a natural evolution.
The two companies were already familiar with one another. In fact, Acclaim was started in January by Robert Waley-Cohen (SCAN 7/7/99), who cofounded Alliance in 1983.
Alliance will stick with Acclaims initial plan to focus on providing mobile, shared-user PET services, but in the future also plans to operate fixed-site systems and enter into joint ventures with medical institutions to provide PET services, according to the firm.
Alliance has secured its first PET scanner, an ECAT EXACT system from Siemens Medical Systems affiliate CTI. The company will soon begin providing PET services to Tri-City Medical Center in Oceanside, CA.
Just a few days prior to its acquisition of Acclaim, Alliance announced that it has entered into a definitive agreement to pursue a recapitalization and a merger, in which Alliances parent company Apollo Management will sell the majority of its shares in Acclaim to an affiliate of venture-capital firm Kohlberg Kravis Roberts & Co. As a result of the deal, approximately 95% of the fully diluted common stock of Alliance, excluding options and warrants, will be retired and the company will be taken private. KKR will own approximately 90% of the new companys common stock, and the management of both Apollo and Alliance will retain approximately 10%.
Alliances debt will be retired as well. After payment of the debt, redemption of the outstanding preferred stock, and payment of transaction expenses, holders of the firms common stock will receive approximately $55 per share in cash.
Following the close of the transaction, senior management of Alliance, including CEO Richard Zehner and president Vincent Pino, will continue to manage the operations of Alliance in their current posts. The deal is subject to customary closing conditions and the obtaining of financing and necessary regulatory consents. Holders of a majority of Alliances shares have approved the transaction, according to Alliance.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.